ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1133

Are We Ready? Changes in the Profile of Gout Patients over the Last 25 Years

Sandra Chinchilla1,2, Irati Urionagüena2,3 and Fernando Perez-Ruiz1,2,3, 1University of the Basque Country (UPV/EHU), Bilbao, Spain, 2BioCruces Health Research Institute, Barakaldo, Spain, 3Rheumatology Division, Hospital Universitario Cruces, Baracaldo, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Aging, Cardiovascular disease, Comorbidity and gout

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Metabolic and Crystal Arthropathies Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:   Gout is a rising cause of hospital admissions and emergency consults. It has even replaced rheumatoid arthritis as the principal rheumatological condition causing hospitalizations.  Some questions arise in this setting: What are the characteristics of our patients? How have they changed over the past years?  Our objective is to analyze possible changes in the clinical profile of gout patients during a period of 25 years.

Methods:   Data was collected from a prospective cohort of gout patients, from a crystal arthritis clinic in a tertiary hospital (reference population: half a million inhabitants). The period, between 1992 and 2016 (n = 1137) was reviewed, with division into five quinquennia (Q). All patients fulfilled ACR/EULAR 2015 gout classification criteria. When entering the cohort, epidemiologic, clinic, laboratory and imaging data are systematically collected. Variables susceptible to change in time were considered: age, gender, gout clinical data, previous admissions due to gout and comorbidities. Complex patients were defined as those who presented at the first visit with polyarticular disease and/or tophi plus chronic kidney disease and/or cardiovascular disease. Quantitative variables were analyzed with ANOVA and Bonferroni correction; qualitative variables with chi-square test. Inclusion of patients to the cohort was approved by the hospital ethics committee. Data from extreme quinquennia are reported (1stQ: 1992-1996 / 5thQ 2011-2016 or 2ndQ: 1997-2001 / 4th: 2006-2010). All results are statistically significant unless stated otherwise.

Results:   Differences were observed regarding age at first visit (1stQ: 54.1 ± 10.9 / 5thQ: 64.6 ± 13.8 years) and gender (1stQ: 2.6% / 5thQ: 12.2% of women, respectively).

Initial comorbidities: See graph 1.

Initial clinical characteristics: See graph 2

The overall prevalence of complex patients was of 67.1%, with increasing incidence through time (1stQ: 53.9% / 5thQ: 77.1%). Globally, less than half of these patients (39.7%) had received urate lowering treatment prior to their first visit.

Conclusion:   The profile of gout patients has notably changed in the past 25 years: we have elder, more complex patients, with higher rates of hospital admissions, with severe forms of disease and important comorbidities. Nevertheless, most of these complex patients have not been appropriately started on urate lowering therapy. When considering these results, we believe that a substantial proportion of gout patients will require specialized attention in the coming years.

Graph 1:

Graph 2:


Disclosure: S. Chinchilla, Beca BBK-BioCruces post MIR curso 2016-2017, 2; I. Urionagüena, None; F. Perez-Ruiz, Asociacion de reumatologos de Cruces, 2,Grünenthal, 5,Grünenthal, 8,Menarini, 5,Menarini, 8.

To cite this abstract in AMA style:

Chinchilla S, Urionagüena I, Perez-Ruiz F. Are We Ready? Changes in the Profile of Gout Patients over the Last 25 Years [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/are-we-ready-changes-in-the-profile-of-gout-patients-over-the-last-25-years/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-we-ready-changes-in-the-profile-of-gout-patients-over-the-last-25-years/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology